Drug intelligence / Profile preview

NCEL-101

Development stage: Preclinical
Lead developer: NewcelX
Modality: Stem Cell Therapies → Cell Therapies

Overview

NCEL-101 is an investigational stem cell therapy being developed by NewcelX for the treatment of Type 1 Diabetes. The therapy is designed to provide a functional source of insulin-producing cells to restore glycemic control in patients. NewcelX has entered into a strategic collaboration with Eledon Pharmaceuticals to evaluate NCEL-101 in combination with an anti-CD40 monoclonal antibody. This combination strategy aims to suppress immune rejection and enable long-term engraftment of the transplanted cells without the requirement for broad-spectrum, chronic immunosuppression.

Beyond the preview

Go deeper on NCEL-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCEL-101.

Explore the full profile